Sleep Disorder-Related Adverse Events Associated with Janus Kinase Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1765; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "JAK inhibitors, particularly tofacitinib, were associated with increased reporting of sleep-related adverse events in the FAERS database. A modest increase in reporting was also observed with abrocitinib, whereas no disproportionality signal was identified for baricitinib. These findings highlight potential differences in sleep-related safety profiles among JAK inhibitors and highlight the need for increased awareness of sleep-related symptoms in patients receiving these therapies."
Adverse events • Cardiovascular • CNS Disorders • Immunology • Inflammatory Arthritis • Insomnia • Rheumatoid Arthritis • Sleep Disorder • Sleep Wake Cycle Disorder • ROR1
|
|
Aisha Mansur1; Rita-Nour Antoine Awad2; Achsah Venite Karra3; Maria Shamsi4
|